Disease progression and survival in patients with stage A carcinomas of the prostate (CAP) have been studied by numerous investigators (Correa et al., 1974; Heaney et al., 1977; Cantrell et al., 1981; Blute et al., 1986; Epstein et al., 1986; Johansson et al., 1992; Jones et al., 1992) . However, no study has compared the survival of patients with stage A CAP with the survival of patients with atypical hyperplasia/ adenosis (AH/A) or patients with benign prostatic hyperplasia (BPH) within the same patient population. To clarify the prognosis of stage A CAP, AH/A and BPH, we compared the long-term survival of patients with Stage A CAP with patients from the same medical centre who had transurethral resections of the prostate (TURP) showing histologically proven AH/A or BPH.
Materials and methods
All patients with stage A CAP diagnosed at the Veterans Administration Medical Center, Temple, Texas, USA, between 1972 and were identified. Of these, 134 did not have additional malignancies at the time of diagnosis capable of influencing survival, and laboratory and radiographic evaluations at the time of diagnosis did not suggest that the CAP had metastasised. All 134 had at least a 5 year followup and were followed annually by the hospital tumour registry to the conclusion of the study in 1992. None was lost to follow-up. Stage A CAP diagnosed in open (suprapubic or retropubic) prostatectomies were not included because the surgical procedure, surgical specimen and method of specimen handling was different from stage A CAP diagnosed from TURP tissue.
Stage A CAP was defined as non-palpable carcinoma found unexpectedly at TURP that showed no evidence of local extension or metastases on staging work-ups. All histological slides of the 134 stage A CAP specimens were reviewed, and 102 contained CAP. The remaining 32 contained atypical, non-malignant glandular proliferations which were reclassified as atypical hyperplasia/adenosis (AH/A) (Helpap, 1980; Brawn, 1982; McNeal, 1988; Bostwick et al., 1993) (Figures 1 and 2 (Brawn et al., 1982 (Greenwald et al., 1974; Brawn et al., 1993 biopsy, unequivocal radiographic evidence or repeatedly elevated acid phosphatase levels (enzyme methods).
Cancer-specific survival was not utilised since this is a 'soft' end point which is not perfect even when autopsies are done on all patients, and is extremely imprecise when autopsies are not performed (Pretlow, 1994) . Survival, which is a 'hard' end point, was calculated with Kaplan-Meier survival curves. Differences in survival between groups was assessed by log-rank tests and proportional hazards regression models. The Wilcoxon two-sample test was used to compare extent of tumour in stage Al and A2 CAP, and Fisher's exact test (two-tailed) was used to assess relative rates of progression between groups. Statistical analysis was performed using the SAS Statistical Package (SAS Institute, Cary, NC, USA).
Results
Seventy-four patients were stage Al, 28 were stage A2 and 32 were AH/A. These groups had mean ages of 70, 75 and 68 years with ranges of 50-89, 59-91 and 54-86 respectively. The control group had a mean age of 66 years with a range of 41-89. Survival curves ( Figure 6 ) were significantly different (P<0.0001, chi-square = 42.8, log-rank test, d.f. = 3) for these groups. Including age in the proportional hazard model with group did not eliminate the effect of group (Wald chi-square = 14.0, P = 0.0028), although age was significantly and negatively associated with survival (Wald chi-square= 40.1, P<0.0001). Analysis of the sources of variation among survival curves showed that most of the difference was due to poorer survival of the A2 group Survival curves for Al and A2 patients (Figure 7 ) with more or less than the median percentage of chips with CAP (8.3% for Al and 11.4% for A2) were not significantly different (P = 0.3 for Al and P = 0.37 for A2, log-rank tests). Likewise, survival curves for Al and A2 patients (Figure 8 ) with more or less than the median resected CAP volume (1.25 g for Al and 3.30 g for A2) were not significantly different (P = 0.33 for Al and P = 0.17 for A2, log-rank tests).
Therapy The stage Al patients and the control group were divided into three groups by age (under 65, 65-74 and over 74 years) and their survival compared. There were 26 Al and 56 controls in the under-65 group, 24 Al and 51 controls in the 65-74 group and 24 Al and 21 controls in the over-74 group. Survival curves ( Figure 9 ) and corresponding log-rank statistics showed no statistical difference in survival in any of the three groups (P = 0.6767, P = 0.084 and P = 0.38 for the three age groups).
Progression to a higher stage occurred in four of the 74 stage Al CAP patients vs eight of 28 stage A2 CAP patients, and was statistically significant (P = 0.003). Although four of the 32 AH/A patients 'progressed' as compared with four of 74 stage Al CAP patients, this was not statistically significant (P = 0.24). The control group contained three patients who were subsequently diagnosed as having CAP. This 'progression' was not statistically different from patients in the stage Al group (P = 0.26). (All above statistics are two-tailed Fisher exact tests.)
Discussion
Stage Al CAP has often been defined as non-palpable WD or MD CAP found unexpectedly at TURP and involving 5% or less of the specimen (Correa et al., 1974; Heaney et al., 1977; Cantrell et al., 1981; Blute et al., 1986; Epstein et al., 1986; Johansson et al., 1992; Jones et al., 1992 u.u unexpectedly at TURP. The survival of patients with stage Al CAP, defined in this manner, was similar to the survival of patients with AH/A and patients with BPH. Stage A2 CAP, defined as non-palpable MD or PD CAP, regardless of amount, found unexpectedly at TURP, was associated with a significantly worse survival than stage Al CAP, AH/A or BPH. Within both stage Al CAP and stage A2 CAP there was no difference in survival between patients with more or less than the median percentage of chips with CAP and no difference in survival between patients who had more or less then the median amount of CAP removed. Our understanding of stage A CAP may have been hindered by studies that included both WD and MD CAP within stage Al CAP. MD CAP not only implies a more aggressive lesion but also a larger lesion, since the volume of CAP increases with dedifferentiation (McNeal et al., 1986; Brawn, 1992) . The current study supported this concept by finding that MD stage A CAP (stage A2) was associated with a markedly worse survival than WD CAP (stage A1) and that MD stage A CAP (stage A2) had a significantly higher percentage of chips containing CAP and a significantly larger amount of resected CAP than WD CAP (stage Al). The grade of CAP is known to dramatically affect prognosis of other stages of CAP (Brawn et al., 1982; 1990 (McNeal et al., 1986; Brawn et al., 1991) . The vast majority of these CAP do not progress to stages B, C or D, and even fewer affect survival. The long indolent course of most stage Al CAP is emphasised by the finding in the current study that younger men (under age 65) with stage Al CAP had the same survival as younger men with histologically proven BPH. Furthermore, the survival of men with TURP showing AH/A or BPH may be adversely affected if they have CAP which was not resected surgically, CAP that was left in the specimen bottle and not studied histologically or if they develop CAP after their TURP. Consequently, patient with stage Al CAP have a malignancy that rarely affects survival, while patients with AH/A or BPH are not without risk of having their survival adversely affected by CAP.
An equally plausible explanation for the similar survivals of patients with stage Al CAP, AH/A and BPH is that some stage Al CAP are not malignant. A histological diagnosis of CAP implies that the pathologist is convinced that the lesion is irrevocably committed to uncontrolled proliferation which will, given time, metastasise. However, in the opinion of the authors of this study, it is possible that some 'welldifferentiated' CAP are, in fact, reversible lesions which will regress with time or are stagnant lesions without the ability to proliferate in an uncontrolled manner and eventually metastasise.
Slightly over one-half of the stage Al and A2 patients in the current study received therapy. Most therapy was radiation and/or hormonal, and only four patients had radical prostatectomies. Stage Al patients receiving therapy were younger and had a better survival than those not receiving therapy. However, when analysed, age, not therapy, correlated best with survival. At any given age, stage Al patients had similar survivals, with or without therapy, as patients with histologically proven BPH. In contrast, age did not affect the survival of patients with stage A2 CAP because the overriding factor in these cases was the aggressiveness of stage A2 CAP.
Progression of stage Al CAP will vary from study to study depending on the thoroughness of follow-up. Furthermore, some patients with stage Al CAP as well as some patients with AH/A or BPH will die of CAP. However, the results of this study suggest that patients with stage Al CAP, with or without therapy, regardless of the percentage of chips containing CAP or the amount of CAP removed at TURP, have an equivalent survival, in each age group, as patients with histologically proven BPH and an overall survival similar to patients with AH/A.
